{"id":401528,"date":"2020-12-17T03:03:17","date_gmt":"2020-12-17T08:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401528"},"modified":"2020-12-17T03:03:17","modified_gmt":"2020-12-17T08:03:17","slug":"arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/","title":{"rendered":"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement"},"content":{"rendered":"

\nARESTAT\u2122 formulated product progressing into clinical trial
\n<\/h2>\n
\n

CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) — Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat\u2122.\u00a0 \u00a0This is the first license under a multi-product development agreement between Inhibrx and Arecor.<\/p>\n

INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of\u00a0Alpha-1 antitrypsin deficiency (AATD).\u00a0\u00a0<\/strong>AATD is an underdiagnosed inherited orphan genetic disease that can cause\u00a0serious lung disease in adults and\/or liver disease at any age. Arestat\u2122 is a world leading, innovative and proprietary formulation technology platform which significantly enhances the properties of therapeutic proteins and peptides.\u00a0 This collaboration demonstrates the unique capability of the Arestat\u2122 technology to deliver superior reformulations of complex fusion proteins in this case for treatment of an orphan disease.<\/p>\n

\u00a0Please click on or paste the following URL into your web browser to view the announcement in full:<\/p>\n

\n http:\/\/www.rns-pdf.londonstockexchange.com\/rns\/8901I_1-2020-12-16.pdf<\/a>\n <\/p>\n

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\u00a0rns@lseg.com<\/u><\/a>\u00a0or visit\u00a0www.rns.com<\/u><\/a>.<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ARESTAT\u2122 formulated product progressing into clinical trial CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) — Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat\u2122.\u00a0 \u00a0This is the first license under a multi-product development agreement between Inhibrx and Arecor. INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of\u00a0Alpha-1 antitrypsin deficiency (AATD).\u00a0\u00a0AATD is an underdiagnosed inherited orphan genetic disease that can cause\u00a0serious lung disease in adults and\/or liver disease at any age. Arestat\u2122 is a world … <\/p>\n

Continue reading “Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401528","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ARESTAT\u2122 formulated product progressing into clinical trial CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) — Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat\u2122.\u00a0 \u00a0This is the first license under a multi-product development agreement between Inhibrx and Arecor. INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of\u00a0Alpha-1 antitrypsin deficiency (AATD).\u00a0\u00a0AATD is an underdiagnosed inherited orphan genetic disease that can cause\u00a0serious lung disease in adults and\/or liver disease at any age. Arestat\u2122 is a world … Continue reading "Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T08:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement\",\"datePublished\":\"2020-12-17T08:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/\"},\"wordCount\":265,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/\",\"name\":\"Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==\",\"datePublished\":\"2020-12-17T08:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk","og_description":"ARESTAT\u2122 formulated product progressing into clinical trial CAMBRIDGE, United Kingdom, Dec. 17, 2020 (GLOBE NEWSWIRE) — Arecor Ltd (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat\u2122.\u00a0 \u00a0This is the first license under a multi-product development agreement between Inhibrx and Arecor. INBRX-101 is a precisely engineered recombinant human Alpha-1 Antitrypsin Fc-fusion protein for the treatment of\u00a0Alpha-1 antitrypsin deficiency (AATD).\u00a0\u00a0AATD is an underdiagnosed inherited orphan genetic disease that can cause\u00a0serious lung disease in adults and\/or liver disease at any age. Arestat\u2122 is a world … Continue reading \"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T08:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement","datePublished":"2020-12-17T08:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/"},"wordCount":265,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/","name":"Arecor's Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==","datePublished":"2020-12-17T08:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzg4OCMzODg2MjI5IzUwMDA2OTY0Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/arecors-partner-inhibrx-exercises-its-option-to-license-a-new-formulation-developed-by-arecor-in-accordance-with-the-terms-of-formulation-development-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Arecor’s Partner Inhibrx Exercises Its Option to License a New Formulation Developed by Arecor in Accordance With the Terms of Formulation Development Agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401528"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401528\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}